A 72-year-old man is brought to the emergency department by his daughter after experiencing a syncopal episode at home. For the past two weeks, he has noted worsening fatigue and lightheadedness. His medical history is significant for open-angle glaucoma, benign prostatic hyperplasia, and osteoarthritis. His current oral medications include tamsulosin and acetaminophen. He explicitly denies starting any new oral medications or making changes to his current regimen. On presentation, his blood pressure is 105/60 mmHg, and his pulse is 42/min. An electrocardiogram reveals profound sinus bradycardia without ischemic changes. Which of the following is the most appropriate next step in evaluating this patient's medical history?
- Inquire about the use of medicated eye dropsAnswer
- BInquire about recent use of over-the-counter cold and sinus preparations
- CAsk about regular consumption of grapefruit juice
- DElicit a history of recent outdoor activities or tick exposures
- EInquire about a family history of sudden cardiac death
Answer
The most appropriate next step is to explicitly ask the patient if he uses medicated eye drops, as topical beta-blockers for glaucoma can cause systemic bradycardia.
The correct response addresses the need to clarify non-oral medication use. This patient has open-angle glaucoma and presents with symptomatic sinus bradycardia. Timolol, a non-selective beta-blocker, is frequently prescribed as an ophthalmic solution for glaucoma. Because these medications drain into the nasal mucosa and bypass hepatic first-pass metabolism, systemic absorption can lead to profound beta-blockade, causing bradycardia and syncope. Patients routinely fail to report eye drops, inhalers, or topical creams when asked broadly about their 'medications,' making direct inquiry a critical step in a thorough medical history evaluation.
Step-by-Step Solution
Key Concept
Patients frequently omit topical, inhaled, or ophthalmic preparations when providing a medication history. Direct and specific inquiry is required when suspecting adverse effects from these routes, such as systemic beta-blockade from glaucoma drops.